Oncolytics Biotech Inc.
ONCYNASDAQHealthcare● Active
$0.84
+$0.00(+0.45%)
Market Cap$84303240
P/E Ratio—
52W High$1.51
52W Low$0.42
Oncolytics Biotech Inc. (ONCY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ONCY · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.08
Est. -$0.05 · -60.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
ONCY reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$0.07 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.05 | -$0.08 | -60.0% | — | — | — |
| ▼ Q1 FY2026 | Mar 30, 2026 | -$0.06 | -$0.08 | -33.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.12 | -$0.10 | +16.7% | — | — | — |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$0.11 | -$0.05 | +54.5% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.09 | -$0.06 | +33.3% | — | — | — |
| ▲ Q1 FY2025 | Mar 7, 2025 | -$0.08 | -$0.07 | +12.5% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.08 | -$0.09 | -12.5% | — | — | — |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$0.07
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.08
EPS Est.
-$0.05
EPS Surpr.
-60.0%
Revenue
—
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.12
EPS Surpr.
+16.7%
Revenue
—
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.11
EPS Surpr.
+54.5%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.09
EPS Surpr.
+33.3%
Revenue
—
Q1 FY2025
Mar 7, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.08
EPS Surpr.
+12.5%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.09
EPS Est.
-$0.08
EPS Surpr.
-12.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q2 FY2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q1 FY2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q4 FY2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2026 | $-0.07 | $-0.07 | $-0.06 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -60.0% | $0.87 | $0.87 | +0.22% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -33.3% | $0.84 | $0.81 | -4.17% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +16.7% | $1.08 | $1.14 | +5.56% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +54.5% | $0.92 | $0.86 | -6.20% |
| ▲ Q2 FY2025 | May 14, 2025 | +33.3% | $0.53 | $0.52 | -3.00% |
| ▲ Q1 FY2025 | Mar 7, 2025 | +12.5% | $0.74 | $0.69 | -6.29% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -12.5% | $1.08 | $1.12 | +3.70% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +12.5% | $1.04 | $1.03 | -0.96% |
Q2 FY2026+0.22%
Report Date
May 14, 2026
EPS Beat/Miss
-60.0%
Price Before
$0.87
Price After
$0.87
Q1 FY2026-4.17%
Report Date
Mar 30, 2026
EPS Beat/Miss
-33.3%
Price Before
$0.84
Price After
$0.81
Q4 FY2025+5.56%
Report Date
Nov 12, 2025
EPS Beat/Miss
+16.7%
Price Before
$1.08
Price After
$1.14
Q3 FY2025-6.20%
Report Date
Aug 8, 2025
EPS Beat/Miss
+54.5%
Price Before
$0.92
Price After
$0.86
Q2 FY2025-3.00%
Report Date
May 14, 2025
EPS Beat/Miss
+33.3%
Price Before
$0.53
Price After
$0.52
Q1 FY2025-6.29%
Report Date
Mar 7, 2025
EPS Beat/Miss
+12.5%
Price Before
$0.74
Price After
$0.69
Q4 FY2024+3.70%
Report Date
Nov 12, 2024
EPS Beat/Miss
-12.5%
Price Before
$1.08
Price After
$1.12
Q3 FY2024-0.96%
Report Date
Aug 1, 2024
EPS Beat/Miss
+12.5%
Price Before
$1.04
Price After
$1.03
Avg Beat Reaction-2.18%
Avg Miss Reaction-0.08%
Beat Rate5 / 8 quarters
Largest Move-6.29% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ONCY ends December
Oncolytics Biotech Inc. (ONCY) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.08 — missing the analyst consensus of $-0.05 by -60.0%. The next ONCY earnings date is expected around September 1, 2026.
Each quarter, investors track ONCY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ONCY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ONCY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ONCY earnings · 5 questionsOncolytics Biotech Inc.'s next earnings report is expected around September 1, 2026. ONCY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ONCY historically reports after market close (AMC).
ONCY earnings datewhen is ONCY earningsONCY next earnings datewhen does ONCY report earningsONCY earnings calendar
▸ Source: FMP · Oncolytics Biotech Inc. SEC filings · US GAAP · Oncolytics Biotech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026